# NanoLuc Binary Technology as a methodological approach: an important new tool for studying the localization of androgen receptor and androgen receptor splice variant V7 homo and heterodimers

**Authors:** Juan Guzman, Katrin Weigelt, Angela Neumann, Philipp Tripal, Benjamin Schmid, Zoltán Winter, Ralph Palmisano, Zoran Culig, Marcus V. Cronauer, Paul Muschler, Bernd Wullich, Helge Taubert, Sven Wach

PMC · DOI: 10.1186/s12885-024-12110-2 · BMC Cancer · 2024-03-19

## TL;DR

This study uses a new tool to investigate how androgen receptor and its variant AR-V7 form dimers and move within cells, especially in response to androgen levels.

## Contribution

The study introduces the use of NanoLuc Binary Technology to explore AR-FL and AR-V7 dimerization and localization in prostate cancer.

## Key findings

- AR-FL homodimers form in the cytoplasm, while AR-V7 homodimers are nuclear.
- Androgen stimulation causes all AR dimers to localize in the nucleus.
- AR-FL and AR-V7 heterodimers are found in the nucleus even without androgens.

## Abstract

The androgen/androgen receptor (AR)-signaling axis plays a central role in prostate cancer (PCa). Upon androgen-binding the AR dimerizes with another AR, and translocates into the nucleus where the AR-dimer activates/inactivates androgen-dependent genes. Consequently, treatments for PCa are commonly based on androgen deprivation therapy (ADT). The clinical benefits of ADT are only transitory and most tumors develop mechanisms allowing the AR to bypass its need for physiological levels of circulating androgens. Clinical failure of ADT is often characterized by the synthesis of a constitutively active AR splice variant, termed AR-V7. AR-V7 mRNA expression is considered as a resistance mechanism following ADT. AR-V7 no longer needs androgenic stimuli for nuclear entry and/or dimerization.

Our goal was to mechanistically decipher the interaction between full-length AR (AR-FL) and AR-V7 in AR-null HEK-293 cells using the NanoLuc Binary Technology under androgen stimulation and deprivation conditions.

Our data point toward a hypothesis that AR-FL/AR-FL homodimers form in the cytoplasm, whereas AR-V7/AR-V7 homodimers localize in the nucleus. However, after androgen stimulation, all the AR-FL/AR-FL, AR-FL/AR-V7 and AR-V7/AR-V7 dimers were localized in the nucleus.

We showed that AR-FL and AR-V7 form heterodimers that localize to the nucleus, whereas AR-V7/AR-V7 dimers were found to localize in the absence of androgens in the nucleus.

The online version contains supplementary material available at 10.1186/s12885-024-12110-2.

## Linked entities

- **Genes:** AR (androgen receptor) [NCBI Gene 367]
- **Diseases:** prostate cancer (MONDO:0005159)

## Full-text entities

- **Genes:** AR (androgen receptor) [NCBI Gene 367] {aka AIS, AR8, DHTR, HPCX3, HUMARA, HYSP1}
- **Diseases:** PCa (MESH:D011471), tumors (MESH:D009369)
- **Cell lines:** HEK-293 — Homo sapiens (Human), Transformed cell line (CVCL_0045)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10949640/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10949640/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC10949640/full.md

---
Source: https://tomesphere.com/paper/PMC10949640